Blood test for early cancer detection using oncRNA analysis
Official title: Prospective Study of oncRNA Stratification of Cancer by Size and Stage
Run by Exai Bio Inc. · NCT05833360 · Data updated 2026-11-12
This study is testing a new blood test that looks for specific markers to see if it can help find cancer earlier in people.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2400 (estimated) |
| Sponsor | Exai Bio Inc. Industry-sponsored |
| Drugs / interventions | radiation |
| Locations | 2 sites (Palo Alto, California and 1 other locations) |
| Status | Recruiting |
| Started | July 14, 2023 |
| Main results expected | July 14, 2030 |
| Study ends | July 14, 2030 |
| Registry record updated | March 18, 2025 |
| Trial ID | NCT05833360 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who are willing to provide informed consent and undergo a blood draw.
✕Probably not a fit
Patients with a prior history of cancer or those currently undergoing cancer treatment are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to develop a blood test that detects cancer through liquid biopsy by analyzing orphan non-coding RNAs (oncRNAs) found in the blood. The study will collect blood samples and medical information from participants with and without cancer to establish a comprehensive understanding of oncRNA patterns. Using artificial intelligence and machine learning, the investigators will identify unique cancer-specific patterns in the blood samples, which could enable early detection of various cancer types. The goal is to improve early intervention strategies and ultimately reduce cancer mortality rates.
Why it matters
Potential benefit: If successful, this test could significantly enhance early cancer detection, leading to timely treatment and improved patient outcomes.
How similar studies have gone: Other studies utilizing liquid biopsy and oncRNA analysis have shown promise in early cancer detection, suggesting a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * Able and willing to provide informed consent * Able and willing to have 35-40 mL of whole blood drawn Exclusion Criteria: * Age \<18 years * Prior history of cancer, except for non-melanoma skin cancer * Prior history of receipt of any blood products within 30 days of enrollment * Receipt of any cancer therapy, e.g., surgical, radiation, or medical including neoadjuvant treatment, prior to study enrollment * Prior history of receipt of any non-cancer system immune modulation therapy within the last 60 days (ex: monoclonal antibodies) * Prior history of organ transplantation * Current or prior pregnancy within the last 12 months * Unable or unwilling to provide informed consent
Where it's running
-
Exai Bio Inc.
Palo Alto, California, United States Recruiting -
Renown Health
Reno, Nevada, United States Recruiting
Study contacts
- Principal investigator: Lee Schwartzberg, MD — Exai Bio Inc.
- Study coordinator: Clinical Operations Team
- Email: clinical-ops@exai.bio
- Phone: 650-204-0423
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.